The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Celgene Corp

Nasdaq: CELG
Last

(U.S.) $121.33

Today's change-14.63 -10.76%
Updated October 20 4:15 PM EDT. Delayed by at least 15 minutes.
 

Celgene Corp

Nasdaq: CELG
Last

(U.S.) $121.33

Today's change-14.63 -10.76%
Updated October 20 4:15 PM EDT. Delayed by at least 15 minutes.

Celgene Corp crosses below 200-day moving average

Celgene Corp closed sharply lower Friday, dropping (U.S.)$14.63 or 10.76% to (U.S.)$121.33 and crossing below its 200-day moving average. Shares have lost 11.09% over the last five days, but have gained 4.82% over the last year to date. This security has performed in-line with the S&P 500 during the last year.

Key company metrics

  • Open(U.S.) $124.50
  • Previous close(U.S.) $135.96
  • High(U.S.) $124.54
  • Low(U.S.) $120.80
  • Bid / Ask(U.S.) $121.50 / (U.S.) $121.64
  • YTD % change+4.82%
  • Volume27,765,072
  • Average volume (10-day)6,578,997
  • Average volume (1-month)4,774,439
  • Average volume (3-month)4,201,929
  • 52-week range(U.S.) $96.93 to (U.S.) $147.17
  • Beta1.83
  • Trailing P/E37.73×
  • P/E 1 year forward16.57×
  • Forward PEG0.78×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $3.22
Updated October 20 4:15 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.25%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2017Q1/2017Q4/2016Q3/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016
Revenue3,2682,9602,9812,983
Total other revenue--------
Total revenue3,2682,9602,9812,983
Gross profit3,1572,8472,8672,875
Total cost of revenue111113114108
Total operating expense2,0051,8522,3522,617
Selling / general / administrative939620685698
Research & development8359951,1351,654
Depreciation / amortization888210587
Interest expense (income), net operating--------
Unusual expense (income)324231471
Other operating expenses, total--------
Operating income1,2631,108628366
Interest income (expense), net non-operating-136-136-136-137
Gain (loss) on sale of assets--------
Other--------
Income before tax1,1301,025499257
Income after tax1,061941429171
Income tax, total69847085
Net income1,061941429171
Total adjustments to net income--------
Net income before extra. items1,061941429171
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1,061941429171
Inc. avail. to common incl. extra. items1,061941429171
Diluted net income1,061941429171
Dilution adjustment--------
Diluted weighted average shares812811802802
Diluted EPS excluding extraordinary itemsvalue per share1.311.160.530.21
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share1.341.210.870.27